<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303978</url>
  </required_header>
  <id_info>
    <org_study_id>DN10007</org_study_id>
    <nct_id>NCT01303978</nct_id>
  </id_info>
  <brief_title>Phase II Proof-of-concept Study of APD421</brief_title>
  <official_title>Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 hours after cisplatin dosing</time_frame>
    <description>No emesis or use of rescue medication</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>APD421 starting dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <description>Single dose</description>
    <arm_group_label>APD421 starting dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients ≥ 18 years of age

          2. Ability and willingness to give written informed consent

          3. Patients scheduled to receive, on day 1 of their chemotherapy, a first cisplatin
             chemotherapy infusion at a dose of 50 mg/m2 or greater

          4. Karnofsky performance score ≥ 60%

          5. Adequate cardiac, hepatic and renal function

               -  QTc interval &lt; 500 ms

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x
                  upper limit normal (ULN)

               -  Bilirubin &lt; 3 x ULN

               -  Creatinine &lt; 2 x ULN

          6. Adequate haematological function

               -  Haemoglobin ≥ 9 g/dL

               -  White blood count ≥ 3.0 x 109/L

               -  Platelet count ≥ 100 x 109/L

          7. For females of child-bearing potential: ability and willingness to use a highly
             effective form of contraception (e.g., abstinence from sexual intercourse, surgical
             sterilisation (of subject or partner) or a double-barrier method of contraception such
             as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in
             conjunction with partner's use of a condom) during the study and for a period of at
             least 48 hours afterwards.

        Exclusion Criteria:

          1. Patients scheduled to receive, prior to or in the 24 hours after cisplatin, any
             chemotherapeutic agent with a high or moderate emetic risk, see Appendix 4.

          2. Patients scheduled to receive paclitaxel or docetaxel

          3. Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening
             or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours
             after cisplatin administration

          4. Patients receiving APD421 for any indication within the last 2 weeks

          5. Patients who are allergic to APD421 or any of the excipients of APD421

          6. Patients with a pre-existing vestibular disorder

          7. Patients being treated with regular anti-emetic therapy including corticosteroids

          8. Patients receiving inhaled corticosteroids, unless started more than one month prior
             to the expected date of study entry

          9. Patients being treated with medications which could induce torsades de pointes,
             including Class Ia antiarrhythmic agents such as quinidine, disopyramide,
             procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and
             other medications such as bepridil, cisapride, thioridazine, methadone, IV
             erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin

         10. Patients being treated with xxx

         11. Patients receiving benzodiazepines, unless on a stable dose for at least one month
             prior to the expected date of study entry

         12. Patients with pre-existing nausea or vomiting in the 24 hours before receiving
             cisplatin chemotherapy, e.g. anticipatory emesis

         13. Patients who are pregnant or breast feeding

         14. Patients with a history of alcohol abuse

         15. Patients with pre-existing, clinically significant cardiac arrhythmia

         16. Any other concurrent disease or illness that, in the opinion of the investigator makes
             the patient unsuitable for the study

         17. Patients who have participated in another study within the previous 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHS Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

